### TAKEDA PHARMACEUTICAL CORP LTD.

ISIN: JP3463000004 WKN: 4502 Asset Class: Stock



--

4-1-1 Dosho-machi, Chuo-Ku

540-8645 Osaka

Fax: +81-6-6204-2880

Web:

http://www.takeda.com

<u>E-mail: -</u>



#### **Company Profile**

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

## Financial figures, Fiscal year: from 01.04. to 31.03.

	2024		2023		2022	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	2,558,580,000,000		2,397,956,000,000		2,593,642,000,000	
Common stock capital		1,676,596,000,000		1,676,345,000,000		1,676,263,000,000
Fixed assets	12,550,212,000,000		11,559,794,000,000		10,584,376,000,000	
Equity capital of a company		7,274,005,000,000		6,354,671,000,000		5,683,523,000,000
Cash and cash equivalents	205,190,000,000		229,557,000,000		849,695,000,000	
Accrued liabilities		158,255,000,000		183,563,000,000		198,046,000,000
Other assets	-		-		-	
Current liabilities		2,313,103,000,000		2,481,940,000,000		2,145,730,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		5,521,685,000,000		5,121,140,000,000		5,348,766,000,000
Different income		-		-		-
Other liabilities		219,721,000,000		204,488,000,000		146,430,000,000
Total assets	15,108,792,000,000	15,108,792,000,000	13,957,750,000,000	13,957,750,000,000	13,178,018,000,000	13,178,018,000,000

## **Balance notes**

	2024	2023	2022
Accounting standard	IFRS	IFRS	IFRS
Employees	49,281	49,095	47,347
Equity ratio	48.15%	45.53%	43.13%
Debt-equity ratio	107.69%	119.63%	131.84%

#### **Others**

	2024	2023	2022
Tax Expense Rate	-197.34%	15.13%	22.77%

# TAKEDA PHARMACEUTICAL CORP LTD.

ISIN: JP3463000004 WKN: 4502 Asset Class: Stock

Income statement			
	2024	2023	2022
Turnover	4,263,762,000,000	4,027,478,000,000	3,569,006,000,000
Net income	144,067,000,000	317,017,000,000	230,059,000,000
EBIT	1,150,801,600	3,139,096,600	2,775,975,800
Operating income before taxes	46,318,000,000	383,720,000,000	317,938,000,000
Cash Flow	640,321,000,000	877,217,000,000	1,021,218,000,000
Net interest income	-142,338,000,000	-130,886,000,000	-137,140,000,000
Research and development expenses	729,924,000,000	633,325,000,000	526,087,000,000
Income taxes	-91,406,000,000	58,052,000,000	72,405,000,000
Result from investments in subsidaries, associates and other	6,473,000,000	-8,630,000,000	-15,367,000,000
Revenues per employee	527,768	500,410	459,817

'S	
Chairman of Supervisory Board	
Member of Supervisory Board	
	Member of Supervisory Board

Members of Management Board				
Christophe Weber	Chairman of Managing Board			
Andrew Plump	Member of Executive Committee			
Costa Saroukos	Member of Executive Committee			
Gabriele Ricci	Member of Executive Committee			
Giles Platford	Member of Executive Committee			
Julie Kim	Member of Executive Committee			
Koki Sato	Member of Executive Committee			
Lauren Duprey	Member of Executive Committee			
Marcello Agosti	Member of Executive Committee			
Milano Furuta	Member of Executive Committee			
Mwana Lugogo	Member of Executive Committee			
Ramona Sequeira	Member of Executive Committee			
Takako Ohyabu	Member of Executive Committee			
Teresa Bitetti	Member of Executive Committee			
Thomas Wozniewski	Member of Executive Committee			
Yoshihiro Nakagawa	Member of Executive Committee			